Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3051 to 3100 of 4138 results for patient

  1. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable ID6596

    In development Reference number: GID-TA11802 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment ID6576

    In development Reference number: GID-TA11773 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Low back pain and sciatica in over 16s: assessment and management (NG59)

    This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.

    NICE guideline
    Last updated
    11 December 2020
    View recommendations

    Sections for NG59

  4. What are the most clinically effective interventions (including social prescribing and structured community support) for managing post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Do any symptoms of post‑COVID‑19 syndrome predict the need for specialist intervention? Are there clusters of symptoms that identify response to interventions in post‑COVID‑19 syndrome? What is the clinical effectiveness of different service models of multimodality/multidisciplinary post‑COVID‑19 syndrome rehabilitation in improving patient‑reported outcomes (such as quality of life)? What is the clinical effectiveness of exercise interventions for people with post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Does early exercise rehabilitation assist in improving symptoms of post‑COVID‑19 syndrome?

    multimodality/multidisciplinary post‑COVID‑19 syndrome rehabilitation in improving patient‑reported outcomes (such as quality of life)?...

    Research recommendation
    Published
    12 November 2021

  5. Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)

    Evidence-based recommendations on eplontersen (Wainzua) for treating hereditary transthyretin-related amyloidosis in adults.

    Technology appraisal guidance
    Published
    27 November 2024
    View recommendations

    Sections for TA1020

  6. Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]

    Awaiting development Reference number: GID-TA11218 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development Reference number: GID-TA11458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development Reference number: GID-TA11087 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    Awaiting development Reference number: GID-TA11500 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400

    Awaiting development Reference number: GID-TA11509 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. The MIST Therapy system for the promotion of wound healing (HTG267)

    Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.

    HealthTech guidance
    Published
    25 July 2011
    View recommendations

    Sections for HTG267

  12. COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Evidence summary: COVID-19 rapid summary
    Published
    5 June 2020

  13. Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism

    Awaiting development Reference number: GID-IPG10456 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  14. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    Awaiting development Reference number: GID-TA10961 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363

    In development Reference number: GID-TA11422 Expected publication date: TBC

    Technology appraisal guidance
    In development

  16. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development Reference number: GID-TA11501 Expected publication date: TBC

    Technology appraisal guidance
    In development

  17. Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]

    In development Reference number: GID-TA11071 Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    In development Reference number: GID-TA11584 Expected publication date:  08 December 2027

    Technology appraisal guidance
    In development

  19. Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406

    In development Reference number: GID-TA11341 Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation

    In development Reference number: GID-IPG10416 Expected publication date:  04 March 2026

    Interventional procedures guidance
    In development

  21. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 15 January 2026.

    Technology appraisal guidance
    In consultation

  22. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

    This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.

    NICE guideline
    Last updated
    11 May 2023
    View recommendations

    Sections for NG18

  23. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development

  24. Long-acting reversible contraception (CG30)

    This guideline covers long-acting reversible contraception. It aims to increase the use of long-action reversible contraception by improving the information given to women about their contraceptive choices.

    Clinical guideline
    Last updated
    2 July 2019
    View recommendations

    Sections for CG30

  25. Schizophrenia: lurasidone (ESNM48)

    Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

    Evidence summary
    Published
    23 September 2014

  26. Vibegron for treating symptoms of overactive bladder syndrome (TA999)

    Evidence-based recommendations on vibegron (Obgemsa) for treating symptoms of overactive bladder syndrome in adults.

    Technology appraisal guidance
    Published
    4 September 2024
    View recommendations

    Sections for TA999

  27. Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies (TA1073)

    Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies.

    Technology appraisal guidance
    Published
    24 June 2025
    View recommendations

    Sections for TA1073

  28. Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery (IPG177)

    Evidence-based recommendations on short-term circulatory support with left ventricular assist devices (LVAD) as a bridge to heart transplantation or recovery. This involves inserting a mechanical device into the chest to help the heart pump blood around the body.

    Interventional procedures guidance
    Published
    28 June 2006
    View recommendations

    Sections for IPG177

  29. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development Reference number: GID-TA11154 Expected publication date: TBC

    Technology appraisal guidance
    In development

  30. PillCam COLON 2 for investigation of the colon through direct visualisation

    In development Reference number: GID-DG10083 Expected publication date: TBC

    Diagnostics guidance
    In development

  31. Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]

    In development Reference number: GID-TA11162 Expected publication date:  28 July 2027

    Technology appraisal guidance
    In development

  32. In-situ normothermic regional perfusion of the abdomen for donor livers following circulatory death

    In development Reference number: GID-IPG10405 Expected publication date: TBC

    Interventional procedures guidance
    In development

  33. MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor

    In development Reference number: GID-IPG10441 Expected publication date: TBC

    Interventional procedures guidance
    In development

  34. In-situ normothermic regional perfusion of the abdomen for donor livers following circulatory death: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 19 December 2025.

    Interventional procedures guidance
    In consultation

  35. Monofocal intraocular lenses for cataract surgery (provisional title)

    In development Reference number: GID-HTE10090 Expected publication date: TBC

    Health technology evaluations
    In development

  36. Published

    The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.

  37. Leukapheresis for inflammatory bowel disease (IPG126)

    Evidence-based recommendations on leukapheresis for inflammatory bowel disease. This involves removing a small number of white blood cells from the person’s blood.

    Interventional procedures guidance
    Published
    22 June 2005
    View recommendations

    Sections for IPG126

  38. Ublituximab for treating relapsing multiple sclerosis (TA1025)

    Evidence-based recommendations on ublituximab (Briumvi) for treating relapsing multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    18 December 2024
    View recommendations

    Sections for TA1025

  39. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development Reference number: GID-TA11410 Expected publication date: TBC

    Technology appraisal guidance
    In development

  40. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]

    In development Reference number: GID-TA11497 Expected publication date: TBC

    Technology appraisal guidance
    In development

  41. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Awaiting development Reference number: GID-TA11343 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  42. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    In development Reference number: GID-TA11336 Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Balloon cryoablation for Barrett's oesophagus

    In development Reference number: GID-IPG10413 Expected publication date:  29 January 2026

    Interventional procedures guidance
    In development

  44. Leadless cardiac pacemaker implantation for bradyarrhythmias

    In development Reference number: GID-IPG10340 Expected publication date:  25 February 2026

    Interventional procedures guidance
    In development

  45. Artificial intelligence software to help detect and characterise colorectal polyps

    In development Reference number: GID-DG10118 Expected publication date: TBC

    Diagnostics guidance
    In development

  46. Percutaneous laser coronary angioplasty (IPG378)

    Evidence-based recommendations on percutaneous laser coronary angioplasty. This involves using a laser to burn away the deposits blocking the blood vessels of the heart.

    Interventional procedures guidance
    Published
    26 January 2011
    View recommendations

    Sections for IPG378

  47. Cryotherapy as a primary treatment for prostate cancer (IPG145)

    Evidence-based recommendations on cryotherapy as a primary treatment for prostate cancer. This involves using cold temperature to freeze and destroy cancer tissue as a first treatment for cancer that hasn't spread far from the prostate.

    Interventional procedures guidance
    Published
    23 November 2005
    View recommendations

    Sections for IPG145

  48. Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion (IPG252)

    Evidence-based recommendations on laser-assisted cerebral vascular anastomosis without temporary arterial occlusion. This involves using a special laser device to create a bypass without the need to temporarily interrupt the blood flow to the brain.

    Interventional procedures guidance
    Published
    27 February 2008
    View recommendations

    Sections for IPG252

  49. Laparoscopic retroperitoneal lymph node dissection for testicular cancer (IPG158)

    Evidence-based recommendations on laparoscopic retroperitoneal lymph node dissection for testicular cancer. This involves using smaller openings in the skin (keyhole surgery) to remove the lymph nodes.

    Interventional procedures guidance
    Published
    22 March 2006
    View recommendations

    Sections for IPG158

  50. The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

    NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system

    Medtech innovation briefing
    Published
    4 February 2014